Michael Seringhaus litigates patent disputes in federal court and before the PTAB for life sciences and pharmaceutical companies, with a particular focus on biologics and biosimilars.

Dr. Seringhaus leverages his PhD in Molecular Biophysics & Biochemistry to represent clients in various fields including:

  • Biologics, particularly antibody pharmaceuticals
  • Biosimilars
  • Small molecule pharmaceuticals
  • Next-generation DNA sequencing

Dr. Seringhaus has experience in all phases of complex patent disputes, both in federal courts and before the Patent Trial and Appeals Board (PTAB). He also provides due diligence analysis and counsels companies on portfolio strategy and litigation risk.

Before entering private practice, Dr. Seringhaus served as a judicial intern for Judge Timothy Dyk of the US Court of Appeals for the Federal Circuit, and clerked for Justice Craig Stowers of the Alaska Supreme Court.

Prior to attending Yale Law School, Dr. Seringhaus’s graduate research focused on computational models to predict essential genes; he also participated in the ENCODE pilot project to identify and analyze functional elements in the human genome.

Dr. Seringhaus’s recent experience includes representing:

  • Janssen (a Johnson & Johnson company) and Genmab in litigation involving their innovative US$2 billion multiple myeloma antibody therapy Darzalex®, resulting in a complete win on summary judgment
  • AbbVie in multiple litigations and inter partes review proceedings involving Humira®, the world’s best-selling drug, including multiple litigations with biosimilar challengers
  • Par Pharmaceutical in litigation adverse to TWi Pharma regarding Megace ES®
  • Roxane Pharmaceuticals in litigation concerning antipsychotic medication iloperidone
  • Life Technologies in several matters including:
    • Parallel US District Court litigation and USPTO reexamination proceedings adverse to Catalyst Assets (fluorescently labeled di-base probes) and Illumina (polyacrylamide/nucleic acid particles)
    • US District Court litigations adverse to Enzo Life Sciences (PCR probes and next-generation DNA sequencing platforms), and Helicos Biosciences (next-generation DNA sequencing platforms); in the latter, Helicos dropped its claims against Life rather than oppose Life's motion for summary judgment of invalidity


  • Genomics Confounds Gene Classification (Cover Article), American Scientist 96:6 466 (2008)
  • E-Book Transactions: Amazon “Kindles” the Copy Ownership Debate, 12 YALE J.L. & TECH. 147 (2009). Selected for publication in West’s Entertainment, Publishing and the Arts Handbook, 2010 ed.
  • Dr. Seringhaus also has published seventeen peer-reviewed scientific articles and commentaries.

Bar Qualification

  • California
  • New York
  • US Patent and Trademark Office


  • JD, Yale Law School, 2010
  • PhD Molecular Biophysics and Biochemistry, Yale University, 2007
  • BS in Biochemistry, Trinity College, University of Toronto, 2000